TherapeuticsMD Inc
TXMD2.290USD
+0.100+4.57%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
26.50MMarket Cap
87.50P/E TTM
More Details of TherapeuticsMD Inc Company
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
TherapeuticsMD Inc Info
Ticker SymbolTXMD
Company nameTherapeuticsMD Inc
IPO dateJan 31, 2001
CEOWalker (Marlan D)
Number of employees1
Security typeOrdinary Share
Fiscal year-endJan 31
Address951 Yamato Road, Suite 220
CityBOCA RATON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33431
Phone15619611900
Websitehttps://www.therapeuticsmd.com/
Ticker SymbolTXMD
IPO dateJan 31, 2001
CEOWalker (Marlan D)
Company Executives of TherapeuticsMD Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Marlan D. Walker, J.D.
Mr. Marlan D. Walker, J.D.
Chief Executive Officer
Chief Executive Officer
73.64K
--
Mr. Cooper C. Collins
Mr. Cooper C. Collins
Independent Director
Independent Director
60.52K
--
Dr. Gail K. Naughton, Ph.D.
Dr. Gail K. Naughton, Ph.D.
Independent Director
Independent Director
8.50K
--
Mr. Joseph Ziegler
Mr. Joseph Ziegler
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
7.50K
--
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Justin Roberts
Mr. Justin Roberts
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Marlan D. Walker, J.D.
Mr. Marlan D. Walker, J.D.
Chief Executive Officer
Chief Executive Officer
73.64K
--
Mr. Cooper C. Collins
Mr. Cooper C. Collins
Independent Director
Independent Director
60.52K
--
Dr. Gail K. Naughton, Ph.D.
Dr. Gail K. Naughton, Ph.D.
Independent Director
Independent Director
8.50K
--
Mr. Joseph Ziegler
Mr. Joseph Ziegler
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
7.50K
--
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Justin Roberts
Mr. Justin Roberts
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
448.00K
57.14%
Non-U.S
336.00K
42.86%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
10.30%
Clearline Capital LP
5.49%
The Vanguard Group, Inc.
3.43%
Tejara Capital Ltd.
3.03%
Adar1 Capital Management LLC
1.81%
Other
75.94%
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
10.30%
Clearline Capital LP
5.49%
The Vanguard Group, Inc.
3.43%
Tejara Capital Ltd.
3.03%
Adar1 Capital Management LLC
1.81%
Other
75.94%
Shareholder Types
Shareholders
Proportion
Hedge Fund
18.44%
Investment Advisor
7.87%
Individual Investor
1.62%
Investment Advisor/Hedge Fund
1.39%
Research Firm
1.13%
Other
69.55%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
82
3.33M
28.78%
-21.58K
2025Q3
82
3.26M
28.17%
-348.35K
2025Q2
88
5.28M
45.63%
+1.46M
2025Q1
93
3.58M
30.94%
-393.28K
2024Q4
95
3.73M
32.32%
-2.03M
2024Q3
99
3.59M
31.15%
-463.34K
2024Q2
121
3.62M
31.37%
-2.25M
2024Q1
209
3.66M
32.13%
-802.21K
2023Q4
230
4.54M
44.12%
-1.60M
2023Q3
274
4.44M
43.31%
-158.22K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rubric Capital Management LP
1.19M
10.3%
--
--
Sep 30, 2025
Clearline Capital LP
635.22K
5.49%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
376.83K
3.26%
-2.17K
-0.57%
Sep 30, 2025
Tejara Capital Ltd.
344.20K
2.97%
-51.00
-0.01%
Sep 30, 2025
Adar1 Capital Management LLC
209.21K
1.81%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
129.59K
1.12%
-528.00
-0.41%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
116.13K
1%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
109.08K
0.94%
--
--
Sep 30, 2025
Walker (Marlan D)
73.64K
0.64%
--
--
Oct 20, 2025
Collins (Cooper C)
60.52K
0.52%
--
--
Oct 20, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
Date
Ex-dividend Date
Type
Ratio
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
